Vaxcyte, Inc.
PCVX
Rankning i aktier
#2080
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Aktiekurs
$64.29
Senast synkroniserad: 2026-10-19
Marknadsvärde
$9.86B
Förändring (1 dag)
1.05%
Förändring (1 år)
49.86%
Land
US
Handel Vaxcyte, Inc. (PCVX)
Kategori
Healthcare
Vinst för Vaxcyte, Inc. (PCVX)
Vinst i Jun 2026 TTM: $-1.06B
Enligt de senaste finansiella rapporterna från Vaxcyte, Inc. är företagets nuvarande vinst $-1.06B. År 2023 hade företaget en vinst på $-402.27M, en minskning jämfört med vinsten år 2022 som var $-223.49M. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för Vaxcyte, Inc. från 2017 till 2026
Vinst vid slutet av varje år
| År | Vinst | Ändra |
|---|---|---|
| 2026 (TTM) | $-1.06B | 129.40% |
| 2024 | $-463.93M | 15.33% |
| 2023 | $-402.27M | 80.00% |
| 2022 | $-223.49M | 123.31% |
| 2021 | $-100.08M | 12.17% |
| 2020 | $-89.22M | 77.46% |
| 2019 | $-50.27M | 70.51% |
| 2018 | $-29.49M | 71.05% |
| 2017 | $-17.24M | 0.00% |
Vinst för liknande företag eller konkurrenter
| Företag | Vinst | Skillnad i vinst | Land |
|---|---|---|---|
| $5.27B | -595.64% |
US
|
|
| $-3.09B | 190.06% |
US
|
|
| $-4.02B | 277.37% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -283.29% |
NL
|
